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Recent studies on parabiosis between young and old animals have discovered that young blood 
has a powerful rejuvenating effect on skeletal and cardiac muscles, as well as on the brain of 
older animals. These results suggest that there is something in the young systemic environment 
that may have anti-aging properties. The results have recently been attributed to a circulating 
protein by the name of GDF11. These results have garnered a lot of attention with the hopes 
that this protein could be the “cure” for aging. With the increasing attention that this concept has 
gathered, it is no surprise that GDF11 also raises a lot of ethical concern and controversy. More 
studies have come out in opposition, suggesting that GDF11 may have been wrongly attributed 
to the rejuvenating results, and may actually be doing more harm than good. Recent 
controversies, related challenges, and a future outlook are highlighted and examined further.  
 
  
Reversing the signs and effects of aging has been sought after by people, including scientists, 
for as long as can be remembered. Cosmetic surgery is slowly becoming one of the largest 
industries in the world, because people are concerned with looking eternally youthful (Plastic 
Surgery Statistics, n.d.). Not only can these results greatly contribute to the superficial needs of 
the general public, but understanding the mechanisms of how we age can also help prevent 
age-related diseases (Ma et al., 2019). It is no surprise that as we age, our bodies slowly start to 
deteriorate. Our bones become frail, and the skeletal muscles surrounding them become weak 
and lose their flexibility (Egerman et al., 2015). Cardiac muscles also degenerate slightly, and 
heart valves become thick and stiff, resulting in our hearts having to work harder to pump blood 
(Egerman et al., 2015). Additionally, our brains undergo a number of changes, causing 
numerous impairments in cognitive functioning (Egerman et al., 2015). The mechanism for 
these degenerative effects, however, is unknown (Egerman et al., 2015).  
 The desire to discover the mechanism, as well as a longing to find a ‘cure’ for aging, has 
led to numerous studies looking for the factor(s) responsible for aging (Egerman et al., 2015). 
Researchers have begun to believe that a circulating protein, growth differentiation factor 11 
(GDF11), which is known to regulate diverse cellular processes, is the cause of these age-
related issues (Egerman et al., 2015). Finding a circulating factor responsible inspires hope for 
novel approaches to treating age-related diseases in humans, and as a result, some scientists 
have attempted to use this protein to slow or even reverse the effects of aging (Ma et al., 2019; 
Egerman et al., 2015). However, increasing reports have shown contradictory data, questioning 
the capacity of GDF11 to reverse age-related degeneration (Ma et al., 2019; Egerman et al., 
2015).  
Transfusion of blood, or of its components, is not a new concept, and has been used as 
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to prescribe bathing in or drinking young blood during the 17th and 18th centuries for rejuvenation 
purposes (Conese et al., 2017). Even stories about Dracula have him drinking young blood in 
order to live forever. Conboy et al., (2003) decided to put this idea to the test and see if there 
was any legitimacy to this old, gruesome technique. Parabiosis is described as a shared 
circulatory system, and GDF11 became the target of multiple studies after Conboy et al. (2003) 
performed a parabiosis study on mice. In this case, two mice, one young and one old, were 
sown together so that blood would circulate through both of them (Conboy et al., 2003). This 
exposed the old mice to all factors present in the young blood, and vice versa (Conboy et al., 
2003). Conboy et al. (2003) performed this study to determine if there were any systemic factors 
in young blood not present in old mice that could be the cause of the effects of aging. Using 
immunofluorescence to better examine the condition of the muscle cells of both mice, Conboy et 
al. (2003) were able to examine the skeletal muscle conditions of mice both before and after the 
procedure.  
 The results were shocking. They showed that the older mice began to regenerate tissue 
stem cells at a higher rate than before, while the young mice began to degenerate at a faster 
rate (Conboy et al., 2003). These results suggest that there are systemic factors in the blood of 
young animals that can modulate the signaling pathways critical to the regeneration of tissue 
cells (Conboy et al., 2003). In addition, the results imply that the negative effects of aging are 
reversible through the alteration of these systemic factors (Conboy et al., 2003).   
Based on the results from the Conboy et al. (2003) study, Sinha et al. (2014) looked 
more specifically into what the regenerative factor for skeletal muscles in young blood could be. 
After performing another parabiosis experiment that garnered the same results as the Conboy 
et al. (2003) study, Sinha et al. (2014) performed a gel electrophoresis assay looking at a 
number of different possible proteins in both old and young mice. They discovered that among 
the proteins found, GDF11 levels decreased significantly in older mice (Sinha et al., 2014).  
Sinha et al. (2014) followed up their study by injuring old mice, treating half of them with 
GDF11, and using the other half as a control. They found that supplementation of GDF11 in 
aged mice restored and regenerated muscle cells and increased the mean size of muscle cells 
of young control mice to 92% (Sinha et al., 2014). However, it did not alter the muscle fibers of 
uninjured young or old mice (Sinha et al., 2014).  
Seeing the emerging evidence that GDF11 might influence aging skeletal muscles 
encouraged further research into the protein, including its effects on other parts of the body. 
More specifically, Loffredo et al. (2013) looked into how, and if, GDF11 could reverse the signs 
of an aging heart. Loffredo et al. (2013) studied the influence of circulating factors using another 
parabiosis study, and after four weeks looked at the results. They found that after one month of 
exposure to the circulation of young mice, cardiac hypertrophy, the thickening and stiffening of 
the heart muscle, in old mice dramatically reverted (Loffredo et al., 2013). 
As with skeletal and cardiac muscles, the nervous system also experiences age related 
degeneration of neural stem cells, resulting in reduced blood flow and neurogenesis, which is 
defined as growth of the nervous tissue (Katsimpardi et al., 2014). Previous research on GDF11 
found that it is essential for embryonic development and neurogenesis, and also participates in 
multiple biological processes of the CNS (Ma et al., 2019). Some researchers have argued that 
restoring the functionality of the specific pathway responsible for the regeneration of cells using 
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2014).  Katsimpardi et al. (2014) tested this theory by performing a study similar to Sinha et al.’s 
(2014) in which they treated older mice with GDF11. The study differed only in that instead of 
looking at skeletal muscles like Sinha et al., they looked at brain capillary endothelial cells. Once 
again, Katsimpardi et al. started their study with another parabiosis examination to ensure that 
the circulation of young blood actually did help regenerate the older mouse, and the results 
once again confirmed that it did (Katsimpardi et al., 2014). Katsimpardi et al. (2014) further 
noted that GDF11 was able to increase blood flow and neurogenesis in aged mice. They did 
find, however, that the results were not as strong and effective as with parabiosis itself, but were 
significant regardless (Katsimpardi et al., 2014).   
Even given all these promising studies and results, there were many controversies 
surrounding GDF11 and its role in combating the effects of aging. In fact, several studies 
looking specifically at GDF11 before 2003, concluded that it does not decrease in concentration 
with age, and that it may contribute to muscle weakness (Rodgers & Eldridge, 2015). In 
addition, it was found that Loffredo et al. (2013) and Sinha et al.’s (2014) studies were not 
reproducible, and they may have been attributing their results to the wrong factor, due to a faulty 
recording procedure (Rodgers & Eldridge, 2015). Many researchers attempted to recreate the 
studies that found GDF11 levels decreased as we age, but were unable to do so, either 
because of the methods used, or the ways in which GDF11 was measured (Hinken et al., 2016).  
Given that there have been two drastically different and contradictory research results 
for the role and expression of GDF11 in the body as we age, a number of scientists questioned 
the methods used, and attempted to reproduce studies. For example, Egerman et al. (2015) 
demonstrated that the methods used, more specifically the western blot analysis used in 
Loffredo et al. (2013) and Sinha et al.’s (2014) studies, were actually not specific to GDF11. 
Consequently, GDF11 has been surrounded by controversy, attributed in part to challenges 
associated with the accurate measurement of its circulating levels and their dissociation from 
circulating myostatin levels (Schafer et al., 2016). In both Loffredo et al. (2013) and Sinha et 
al.’s (2014) study, the antibody used to bind to GDF11 (in order to determine its expression in 
the body) also binds to the protein myostatin, and one cannot distinguish between the two 
(Egerman et al., 2015). Myostatin is known to diminish as we age, and so not being able to 
differentiate between myostatin and GDF11 could be the reason for the results suggesting that 
GDF11 decreases as well (Egerman et al., 2015). 
Egerman et al. (2015) found a way to specifically detect levels of GDF11 in the blood of 
humans using an immunoassay technique, and tested it on humans, rather than mice. When 
comparing the expression of GDF11 in 60-year-olds versus 20-30-year-olds, they found that 
there were significantly higher levels of GDF11 in older humans than in younger humans 
(Egerman et al., 2015). This coincided with the earlier studies looking at GDF11 (Egerman et 
al., 2015). To further solidify their findings, they reproduced the same study Sinha et al. (2014) 
did, in which they administered GDF11 treatment or a control treatment (in which there should 
be no effect) to aged mice for 7 days (Egerman et al., 2015). The only difference was that they 
used their immunoassay technique to measure the expression of GDF11 (Egerman et al., 
2015). This experiment concluded that GDF11 levels in older animals were not diminishing, and 
there were no differences when observing regenerative capacity of skeletal muscles between 
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Schafer et al. (2016) added more support to the result that GDF11 levels actually 
increase as we age by using their own specific immunoassay technique, and once again testing 
on humans. Schafer et al. (2016) demonstrated that people with higher levels of GDF11 were 
more likely to be frail and have diabetes or prior cardiac conditions. Additionally, those with high 
levels of GDF11 experienced higher disease burden, reduced resiliency, and elevated post-
operative risk (Schafer et al., 2016). In humans, it was also demonstrated that levels of GDF11 
do not significantly differ between men and women (Schafer et al., 2016). Schafer et al.’s (2016) 
study further revealed that myostatin levels decreased as people aged, and were the lowest in 
those experiencing sarcopenia, or age-related muscle degeneration.  
Egerman et al. (2015) finalized their research by performing a study in which they 
increased GDF11 levels in young mice (which in their study, had lower levels of GDF11 than 
older mice) and showed that GDF11 was harmful toward muscle repair in young mice (Egerman 
et al., 2015; Rodgers & Eldridge, 2015). They noticed that muscle fibers in GDF11-treated mice 
actually began to shrink due to a decreased number of muscle cells, and in regenerating 
muscle, GDF11 treatment was associated with a greater frequency of small fibers (Egerman et 
al., 2015). Given these studies, it is possible that GDF11 could even be the cause of some of 
the effects of aging, and therefore we should possibly be looking at ways to block it, rather than 
increasing it (Egerman et al., 2015). Clearly, further investigation is needed to fully clarify 
whether or not, and under what conditions, GDF11 is a factor that beneficially regulates muscle 
activity during aging.  
Not only were some methods in earlier studies faulty, but information from these studies 
was also taken out of context. For example, Conboy et al. (2003) from the first parabiosis study 
did an interview in which they addressed some of their concerns with the way their study had 
influenced other researchers (Chen, 2019). While there was significant evidence suggesting that 
there could be a factor in young blood that could potentially reverse the signs of aging, Conboy 
et al. (2003) urged the public to take the results with a grain of salt (Chen, 2019). They 
explained that during a parabiosis study, not only do you share the same circulatory system, but 
you also share two of every organ (Chen, 2019). The old mouse in their study could have 
seemed restored and youthful because it was also able to utilize a young heart, young lungs, 
etc. (Chen, 2019). In addition, a very important, but usually neglected, result from their study 
was that the young mice began to deteriorate and die off when sown to older mice (Chen, 
2019).  
Conboy et al. (2003) also informed the public that even though their study did show 
positive results, and that there is reason for further research into what systemic factors in young 
blood could be causing the regeneration of old tissue, they warned that there are also many 
possible side effects of blood transfusions if not administered carefully (Chen, 2019). While the 
mice that were part of the study were inbred and very compatible, people are not genetically 
matched (Chen, 2019). Careless use of blood transfusion could therefore result in dangerous 
side effects, such as allergic reactions, infection, blood transmitted diseases, etc. (Chen, 2019). 
There are many issues that can arise with blood transfusions in humans if the proper 
precautions aren’t taken to assure the compatibility of the blood from the donor and the recipient 
(Pardi, 2017). Conboy et al. (2003) emphasized that they were purely in the research phase, 
stating that there are a lot of variables to consider when administering blood transfusions, and 
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For humans, eternal youth has been sought after for centuries. With the societal 
standards of beauty changing, and with a growing proportion of the population aging, limiting the 
effects of aging is more important now than ever before. That being said, small advancements 
towards this create a lot of publicity and, if in the wrong hands, can be detrimental. The media 
got ahold of these studies and, when transmitting the information to the public, only used the 
eye-catching and interesting results (Pardi, 2017). The media blew up with the story that 
scientists had found the “cure” for aging in young blood, while neglecting to mention the 
procedures and uncertainties behind the research, or that it had not been tested on humans 
(Pardi, 2017).  
Neglecting to give the whole truth of these studies was misleading and could have 
caused people to engage in risky activity when there is still research (including human trials) to 
be done. The exaggerated claims made in the media can be dangerous on a number of levels. 
One example is a large company by the name of Ambrosia (Ivy Plasma, n.d.). 
Ambrosia began selling human blood plasma from younger donors with the promise of 
anti-aging and rejuvenating effects to people above the age of 35 for $8,000 (Ivy Plasma, n.d.). 
Not only was it extremely unethical to ask people to pay large sums of money to unknowingly be 
part of the first human trials, but the company also made false promises to their customers (Ivy 
Plasma, n.d.) The founder, Jesse Karmazin, who is not a licensed doctor, made positive claims 
about the results of these human trials, without posting any of the scientific results as proof (Ivy 
Plasma, n.d.). Karmazin also held back information about the specifics of the tests themselves, 
and it is still unclear how they were done and how they affected the patients (Ivy Plasma, n.d.). 
Companies such as Ambrosia exploit innocent, gullible people, and are the reason the FDA had 
to send out a report stating that this procedure was not FDA approved because of lack of 
research and unknown long term results (Gottlieb, 2019).  
Research studies utilizing parabiosis have brought humans closer to the ‘fountain of 
youth’ than ever before, but there are still a number of steps to take, and a number of studies to 
be done, before treatments are available (Hofmann, 2018). Future research should consider the 
idea that the rejuvenating factor (or a combination of factors) may not be limited to the blood 
(Ma et al., 2019). Other factors should be considered because substances found in plasma 
come from both blood cells and peripheral organs (Ma et al. 2019). As is well understood, blood 
is composed of blood cells and plasma (Ma et al. 2019). It would be appropriate to research the 
effects when using only blood cells, or only plasma, or a combination of both (Ma et al. 2019).  
Also, using research done on mice to men requires careful consideration (Hofmann, 
2018). Parabiosis and blood transfusions pose a number of problems, and the concept of using 
internal substances in some people as a means to rejuvenate others calls for ethical reflection 
(Hofmann, 2018). Considering that blood transfusion is a clinically approved technique, 
transfusion of young blood could potentially be a novel way to combat or prevent aging (Ma et 
al., 2019). However, it is worth mentioning that if this functions properly, there is going to be a 
huge demand for young blood, for both recreational and medical use (Ma et al., 2019). This 
would create a demand that will likely not be able to be kept up with, which could possibly result 
in other dangerous outcomes (Ma et al., 2019). Promising parabiosis research indicates that we 
may be closer to eternal youth than ever before (Hofmann, 2018). But, it is far too early to 
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